<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624375</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001399</org_study_id>
    <secondary_id>53354</secondary_id>
    <nct_id>NCT02624375</nct_id>
  </id_info>
  <brief_title>Immune Response to Shingles Vaccination</brief_title>
  <official_title>Immune Response to Shingles Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about the immune response to varicella zoster
      virus (VZV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants 70 years of age or older will receive the FDA-approved shingles vaccine
      (Zostavax). Blood samples and optional skin biopsies will be obtained before and after
      vaccination to study the immune responses to shingles vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Blood</measure>
    <time_frame>6 months</time_frame>
    <description>To determine if Zostavax, when given as FDA indicated, boosts VZV-specific T-cells in the blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Skin</measure>
    <time_frame>4 weeks</time_frame>
    <description>To determine if shingles disease boosts the local level of VZV-specific T cells in skin 4 weeks after Zostavax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Due to Zostavax</measure>
    <time_frame>6 months</time_frame>
    <description>To measure the occurrence of adverse events after Zostavax.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Shingles</condition>
  <arm_group>
    <arm_group_label>10 persons over 70 years of age that received Zostavax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 persons over 70 years of age that received Zostavax (single 0.65-mL dose subcutaneously in the deltoid region of the upper arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoster Vaccine Live</intervention_name>
    <arm_group_label>10 persons over 70 years of age that received Zostavax</arm_group_label>
    <other_name>ZOSTAVAX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  70 years of age or older.

          -  History of chickenpox.

        Exclusion Criteria

          -  Previous vaccination with Zostavax or with the chickenpox vaccine.

          -  History of ever having had shingles.

          -  Been in close contact with a person who had chickenpox or shingles in the past 5
             years.

          -  VZV seronegative

          -  Taking systemic suppressive regular doses of drugs with anti-VZV activity such as
             acyclovir, famciclovir, or valacyclovir. Episodic use is allowed. For Cohort 1:
             medication cannot be taken 24 hours prior to or 30 days after receiving Zostavax per
             CDC recommendations.

          -  HIV seropositive.

          -  Hepatitis C infection or active Hepatitis B infection.

          -  History of a life-threatening allergic reaction (anaphylactic/anaphylactoid reaction)
             to gelatin, neomycin, or any other component of shingles vaccine. Neomycin allergy
             manifested as contact dermatitis is not an exclusion.

          -  Has immunosuppression as a result of an underlying illness (e.g. leukemia, lymphoma or
             other malignant neoplasms) or treatment with immunosuppressive or cytotoxic drugs, or
             use of anticancer chemotherapy or radiation therapy.

          -  Has long-term use of oral or parenteral steroids (&gt;7 days), or high-dose inhaled
             steroids (&gt;800 mcg/day of beclomethasone dipropionate or equivalent) within the
             preceding 6 months (nasal and topical steroids are allowed).

          -  Women of child-bearing potential only: pregnant or planning to become pregnant 3
             months post vaccination

          -  Donated blood in the past 8 weeks or planning to donate blood during the study

          -  Weighs less than 110 lbs

          -  Has any condition or medical history that would, in the opinion of the site principal
             investigator place the subject at an unacceptable risk of injury or render the subject
             unable to meet the requirements of the protocol.

        Additional exclusions for optional skin biopsy:

          1. Has an acute or chronic medical condition that, in the opinion of the investigator,
             would render biopsies unsafe

          2. History of coagulopathy or taking medication that may cause bleeding (long term
             aspirin, heparin, coumadin)

          3. History of keloid formation or excessive scarring

          4. History of frequent cellulitis or boils (&gt;3 episodes in past 2 years) requiring
             antibiotic therapy.

          5. Allergy to lidocaine, silver nitrate, or mupirocin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Washington Virology Research Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <results_first_submitted>November 12, 2019</results_first_submitted>
  <results_first_submitted_qc>December 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 5, 2019</results_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Christine Johnston</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 16, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02624375/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred from September 2016 to January 2018. Recruitment was done by placing flyers at retirement homes and by contacting persons over 70 who had previously been enrolled in research studies including giving informed written consent to be re contacted for future studies.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Persons 70 and Over Receiving Zostavax (Zoster Vaccine Live)</title>
          <description>We administered Zostavax at the FDA approved dose and route to an FDA-indication-approved population, namely healthy adults 70 and over. We administered vaccine to 10 persons as proposed in the protocol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Person 70 and over receiving Zostavax</population>
      <group_list>
        <group group_id="B1">
          <title>Persons 70 and Over Receiving Zostavax (Zoster Vaccine Live)</title>
          <description>We administered Zostavax at the FDA approved dose and route to an FDA-indication-approved population, namely healthy adults 70 and over. We administered vaccine to 10 persons as proposed in the protocol.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.5" lower_limit="70" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>no history of shingles or shingles vaccination</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Blood</title>
        <description>To determine if Zostavax, when given as FDA indicated, boosts VZV-specific T-cells in the blood</description>
        <time_frame>6 months</time_frame>
        <population>10 persons 70 and older who received Zostavax</population>
        <group_list>
          <group group_id="O1">
            <title>Persons 70 and Over Receiving Zostavax (Zoster Vaccine Live)</title>
            <description>We administered Zostavax at the FDA approved dose and route to an FDA-indication-approved population, namely healthy adults 70 and over. We administered vaccine to 10 persons as proposed in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Blood</title>
          <description>To determine if Zostavax, when given as FDA indicated, boosts VZV-specific T-cells in the blood</description>
          <population>10 persons 70 and older who received Zostavax</population>
          <units>percentage of CD4 T cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="0" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Skin</title>
        <description>To determine if shingles disease boosts the local level of VZV-specific T cells in skin 4 weeks after Zostavax</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Persons 70 and Over Receiving Zostavax (Zoster Vaccine Live)</title>
            <description>We administered Zostavax at the FDA approved dose and route to an FDA-indication-approved population, namely healthy adults 70 and over. We administered vaccine to 10 persons as proposed in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Th1 Cytokine Positive VZV-specific CD4 T-cells in Skin</title>
          <description>To determine if shingles disease boosts the local level of VZV-specific T cells in skin 4 weeks after Zostavax</description>
          <units>Percentage of CD4 T cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Due to Zostavax</title>
        <description>To measure the occurrence of adverse events after Zostavax.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Persons 70 and Over Receiving Zostavax (Zoster Vaccine Live)</title>
            <description>We administered Zostavax at the FDA approved dose and route to an FDA-indication-approved population, namely healthy adults 70 and over. We administered vaccine to 10 persons as proposed in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Due to Zostavax</title>
          <description>To measure the occurrence of adverse events after Zostavax.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Persons 70 and Over Receiving Zostavax (Zoster Vaccine Live)</title>
          <description>We administered Zostavax at the FDA approved dose and route to an FDA-indication-approved population, namely healthy adults 70 and over. We administered vaccine to 10 persons as proposed in the protocol.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christine Johnston, Associate Professor</name_or_title>
      <organization>University of Washington</organization>
      <phone>206 520 4340</phone>
      <email>cjohnsto@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

